Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's positive outlook is supported by its operational sales growth of 11.5% in 4Q25, despite facing a 650 basis points headwind from generic competition for its Stelara product. The company anticipates substantial capital allocation toward its MedTech division following the planned separation of its Orthopedic business, which is expected to enhance revenue growth and bolster its competitive position in key areas such as Cardiovascular, Surgery, and Vision. Additionally, updated revenue projections for 2026 have been raised to $100.42 billion, driven by strong performance in therapeutic areas like Immunology and the potential of new drugs, indicating a robust trajectory for earnings expansion.

Bears say

Johnson & Johnson's financial outlook is concerning due to several fundamental risks impacting its growth potential. The anticipated loss of exclusivity for key pharmaceutical products, combined with underwhelming performance from its pipeline and MedTech division, raises questions about the company's ability to sustain organic revenue growth. Additionally, ongoing litigation issues and the repercussions of potential mergers and acquisitions present added volatility, further complicating the financial landscape for the healthcare giant.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.